secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061104
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q3 net loss $18.3M, cash $60.5M, CEO salary cut to $100k, workforce reduced 25%
--------------------------------------------------------------------------------

- Net loss $18.3M in Q3 2023 vs $16.2M in Q3 2022; R&D spend $11.2M, cash burn extends runway into 2025.
- CEO Talat Imran salary reduced from $520k to $100k through 2024 or until $50M is raised.
- Strategic prioritization: discontinue RT-101, pause RT-105/RT-110, workforce cut ~25%.
- RT-102 Phase 2 starts year-end 2023; RT-111 Phase 1 topline expected Q1 2024; RaniPill HC Phase 1-ready 2H 2024.
- RaniPill HC achieved >90% drug delivery success in preclinical studies with adalimumab and interleukin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/0000950170-23-061104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/rani-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer